Placeholder Banner

BIO Statement on PIPs Rule: EPA Misses Opportunity to Advance Food, Ag Innovation

May 25, 2023
Media Contact
Lynne Headshot

The following statement concerning the Environmental Protection Agency’s final rule on regulation of Plant Incorporated Protectants (PIPs) under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) may be attributed to John Murphy, chief policy officer and deputy general counsel for the Biotechnology Innovation Organization (BIO).

“EPA’s revisions to the PIPs regulations come at a critical time for technology developers and society as we innovate to meet global challenges including strengthening food security and climate adaptation, mitigation and resilience. EPA had an opportunity to streamline regulations of pesticidal substances in plants and expand exemptions that help bring new, innovative products made with precise gene editing tools to market. The revisions could have helped biotechnology harness the power of science to advance the bioeconomy and feed the world more securely and sustainably, goals that President Biden has declared in his Executive Order on biotechnology and innovation.  

“Unfortunately, the agency’s final rule is a hugely missed opportunity. EPA’s rule inexplicably holds PIPs produced via biotechnology to a different standard than the same substances produced via plant breeding. This approach of holding the same or similar products to different standards merely due to their production method is not supported by science. EPA is imposing an extremely narrow exemption and burdensome data requirements that render this an exemption in name only.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…